ArticleCNS neuroscience & therapeutics2026
Integrating Pharmacovigilance Data Mining and Mendelian Randomization to Identify Risk Profiles and Causal Targets of Opioid-Induced Delirium.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOpioid-induced delirium represents a major clinical challenge with substantial implications for patient safety and outcomes. An integrated evaluation combining pharmacovigilance and genetic evidence remains limited. This study aimed to systematically assess delirium risk across different opioids and to elucidate underlying molecular mechanisms by integrating real-world safety data with Mendelian randomization (MR) analysis.
methodsUsing data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) spanning 2004-2025, disproportionality analyses (reporting odds ratio, proportional reporting ratio, and empirical Bayes geometric mean) and multivariable logistic regression were conducted to quantify delirium risk associated with 12 commonly used opioids. Network pharmacology was subsequently applied to identify candidate pathways and targets, followed by MR analyses based on FinnGen data to investigate potential causal relationships between key target genes and delirium.
resultsSubstantial heterogeneity in delirium risk was observed across opioids. Methadone showed the strongest association with delirium (EBGM 25.98) and the highest independent risk after adjustment (adjusted odds ratio 29.79), followed by oxycodone. Stronger risk signals were consistently observed among older individuals (> 55 years) and females. Mechanistic analyses highlighted pathways related to xenobiotic metabolism and neuroinflammation, particularly the PI3K-Akt signaling pathway. MR analyses identified COMT as a risk-associated gene for delirium (OR 1.25), whereas MYD88 and CYP1B1 demonstrated potential protective effects.
conclusionsMarked differences in delirium risk exist among opioids. COMT, MYD88, and CYP1B1 were identified as key candidate genes underlying opioid-associated delirium. These findings provide a genetic and mechanistic framework to support clinical risk stratification and the development of precision prevention and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.